Kazia Therapeutics to Host Virtual Event on NDL2 Program
Kazia Therapeutics announced it will host a virtual event on December 2, 2026, to provide a management overview of its NDL2 program, a novel nuclear PD-L1 protein degrader.
Stocks · News reference
Kazia Therapeutics has been recognized as the 'Drug Discovery Company of the Year' in the 2026 BioTech Breakthrough Awards for its innovative approach to cancer therapeutics.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Kazia Therapeutics announced it will host a virtual event on December 2, 2026, to provide a management overview of its NDL2 program, a novel nuclear PD-L1 protein degrader.
Kazia Therapeutics has received acceptance for two research abstracts regarding its lead candidate, paxalisib, for poster presentation at the 2026 San Antonio Breast Cancer Symposium.
Kazia Therapeutics announced that its CEO and Head of Corporate Strategy & Development will participate in a fireside chat at the upcoming Guggenheim 3rd Annual Healthcare Innovation Conference.
Guggenheim has initiated coverage on Kazia Therapeutics with a 'Buy' rating and a price target of $35.00 per share.
Analysts initiate coverage: Buy on AIR Global, Robinhood and Kazia; Outperform on Equinix; Neutral on Zscaler, with price targets.